Hp-𝜷-CD-Voriconazole In Situ Gelling System for Ocular Drug Delivery: In Vitro, Stability, and Antifungal Activities Assessment

Table 3

In vitro permeation of Voriconazole from in situ gels through millipore membrane filter and freshly excised goat cornea.

% Drug permeation*
Formulations	Millipore paper		Goat cornea		Corneal hydration (%)
	𝑡1	𝑡10	𝑡1	𝑡4
VG1	22.01 ± 0.21	64.98 ± 0.65	16.89 ± 0.27	30.82 ± 0.27	77.03 ± 1.9
VG2	20.27 ± 0.23^††	63.82 ± 1.07^††	14.61 ± 0.15^††	28.58 ± 0.12^††	79.80 ± 0.6
VG3	18.47 ± 0.10^††	59.01 ± 0.35^††	12.82 ± 0.12^††	27.46 ± 0.19^††	78.71 ± 2.3
VG4	21.98 ± 0.19^††	60.32 ± 0.80^††	15.84 ± 0.08^††	29.31 ± 0.26^††	75.69 ± 0.5
VG5	19.89 ± 0.08^††	58.13 ± 0.27^††	13.64 ± 0.41^††	27.80 ± 0.46^††	74.90 ± 1.7
VG6	18.24 ± 0.13^††	52.96 ± 0.38^††	12.14 ± 0.52^††	25.94 ± 0.72^††	76.33 ± 3.1
VG7	20.69 ± 0.21^††	58.30 ± 0.39^††	15.04 ± 0.43^††	27.37 ± 1.70^††	77.05 ± 0.9
VG8	15.10 ± 0.12^††	51.47 ± 0.47^††	13.57 ± 0.46^††	27.60 ± 0.47^††	79.02 ± 1.7
VG9	12.64 ± 0.18^††	49.84 ± 0.49^††	9.93 ± 0.10^††	19.74 ± 0.21^††	75.90 ± 0.6

∗Mean ± SD, 𝑛 = 3.
𝑡₁—cumulative percent drug after 1 hr; 𝑡₁₀—cumulative percent drug after 10 hr; 𝑡₄—cumulative percent drug after 4 hr.
†Statistically significant difference at 𝑃<0.05.
††Statistically significant difference at 𝑃<0.01.
†††Statistically significant difference at 𝑃<0.001 from control (VGI containing 15% PF-127, 14% PF-68, 0.5% sodium alginate) as determined by one-way ANOVA followed by Dunnett’s test.